Literature DB >> 6639844

Binding of theophylline and its metabolites to human plasma proteins.

U Gundert-Remy, R Hildebrandt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6639844      PMCID： PMC1428064          DOI： 10.1111/j.1365-2125.1983.tb02220.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  8 in total

1.  Interactions of xanthine molecules with bovine serum albumin.

Authors:  M L EICHMAN; D E GUTTMAN; Q VAN WINKLE; E P GUTH
Journal:  J Pharm Sci       Date:  1962-01       Impact factor: 3.534

2.  Effect of pH on the binding of theophylline to serum proteins.

Authors:  J J Vallner; W A Speir; R C Kolbeck; G N Harrison; E D Bransome
Journal:  Am Rev Respir Dis       Date:  1979-07

3.  Plasma concentrations of the urate-binding alpha 1-2 -globulin in patients with different types of primary gout as compared to healthy control subjects.

Authors:  J O Alvsaker; J E Seegmiller
Journal:  Eur J Clin Invest       Date:  1972-01       Impact factor: 4.686

4.  The binding of urate to plasma proteins determined by means of equilibrium dialysis.

Authors:  J R Klinenberg; I Kippen
Journal:  J Lab Clin Med       Date:  1970-03

5.  Competitive action of contrast media on the uric acid-albumin binding.

Authors:  E Boldrini; P Tirone
Journal:  J Pharmacol Methods       Date:  1982-01

6.  Nonlinear theophylline elimination.

Authors:  D D Tang-Liu; R L Williams; S Riegelman
Journal:  Clin Pharmacol Ther       Date:  1982-03       Impact factor: 6.875

7.  Factors influencing theophylline serum protein binding.

Authors:  L M Shaw; L Fields; R Mayock
Journal:  Clin Pharmacol Ther       Date:  1982-10       Impact factor: 6.875

8.  Non-linear elimination processes of theophylline.

Authors:  U Gundert-Remy; R Hildebrandt; N Hengen; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953
  8 in total
  6 in total

1.  Absence of a clinically significant interaction between theophylline and furosemide.

Authors:  U A Jänicke; B Krüdewagen; A Schulz; U Gundert-Remy
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Pharmacokinetics of theophylline and its metabolites in a patient undergoing continuous ambulatory peritoneal dialysis.

Authors:  T B Vree; M Martea; R G Tiggeler; Y A Hekster; J C Hafkenscheid
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

3.  Protein binding of theophylline.

Authors:  D C Buss; P Ebden; S Baker; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

4.  Variability of the serum protein binding of theophylline in patients with asthma and cystic fibrosis.

Authors:  J Blanchard; S Harvey; W J Morgan
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

5.  Nonlinear renal excretion of theophylline and its metabolites, 1-methyluric acid and 1,3-dimethyluric acid, in rats.

Authors:  H J Kuh; C K Shim
Journal:  Arch Pharm Res       Date:  1994-04       Impact factor: 4.946

6.  A "Single-Use" Ceramic-Based Electrochemical Sensor Chip Using Molecularly Imprinted Carbon Paste Electrode.

Authors:  Aaryashree No Family Name; Yuuto Takeda; Momoe Kanai; Akihiko Hatano; Yasuo Yoshimi; Masahito Kida
Journal:  Sensors (Basel)       Date:  2020-10-16       Impact factor: 3.576
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.